8-K: NeuroMetrix to be Acquired by electroCore in Merger Deal

NeuroMetrix has agreed to be acquired by electroCore, with shareholders receiving cash and contingent value rights.

Summary

• NeuroMetrix has entered into a definitive merger agreement to be acquired by electroCore.
• The transaction is expected to close late in the first quarter of 2025.
• NeuroMetrix shareholders will receive cash equal to the company's net cash balance at closing, estimated to be approximately $9 million, subject to adjustments.
• Shareholders will also receive one contingent value right (CVR) per share.
• Each CVR represents the right to receive future net proceeds from any divestiture of the DPNCheck platform and certain royalties on net sales of prescription Quell products over the first two years following the closing of the transaction, up to an aggregate maximum of $500,000.
• The final net cash balance will be determined at closing based on a formula in the merger agreement.
• The transaction is subject to shareholder approval, NeuroMetrix having at least $8 million of net cash at closing, and the filing of NeuroMetrix's Form 10-K for the fiscal year ended December 31, 2024, as well as other customary closing conditions.

Sentiment

Score: 7

Explanation: The document presents a positive outcome for NeuroMetrix shareholders, with a return of cash and potential upside through CVRs. The language is generally optimistic, highlighting the benefits of the transaction. However, there are also risks and uncertainties associated with the deal, which temper the overall sentiment.

Positives

• The transaction allows NeuroMetrix to efficiently return balance sheet cash to shareholders.
• Shareholders have potential upside through the contingent value rights (CVRs).
• The transaction is expected to expand patient access to Quell wearable neuromodulation technology through electroCore's commercial channel.
• The company expects to divest the DPNCheck business, ensuring continued access to its diagnostic capabilities.

Negatives

• The DPNCheck platform is not included in the acquisition and will be divested.
• The final net cash balance is subject to adjustments and will be determined at closing.

Risks

• The transaction may not be completed in a timely manner or at all.
• The failure to satisfy the conditions to the consummation of the transaction, including shareholder approval and regulatory approvals, could prevent the merger.
• The merger agreement may be terminated under certain circumstances, potentially requiring the Company to pay a termination fee.
• There are risks related to obtaining the necessary financing to complete the merger.
• The announcement or pendency of the transaction may affect the Companys business relationships and operating results.
• The proposed transaction may disrupt current plans and operations.
• The transaction may divert managements attention from the Companys ongoing business operations.
• Legal proceedings may be instituted against the Company related to the merger agreement or the transaction.

Future Outlook

The transaction is expected to close late in the first quarter of 2025, with NeuroMetrix becoming a wholly-owned subsidiary of electroCore. NeuroMetrix shareholders will receive cash and contingent value rights, with potential upside from the CVRs.

Management Comments

• This announcement represents the culmination of our strategic review process announced in February 2024, and marks a positive outcome for the Companys shareholders.
• Through this transaction, we will efficiently return balance sheet cash to our shareholders while providing potential upside through the CVR.
• A further advantage of this transaction is that we expect patients with chronic pain to have expanded access to our novel and proprietary Quell wearable neuromodulation technology through the commercial channel that electroCore has built.
• Although the DPNCheck platform is not included in the acquisition, we expect to divest this business such that patients and physicians continue to benefit from its unique and important diagnostic capabilities.

Industry Context

This acquisition reflects a trend of consolidation in the bioelectronic medicine and wellness industry, with electroCore expanding its portfolio through the acquisition of NeuroMetrix and its Quell technology. The divestiture of the DPNCheck platform suggests a focus on core business areas for both companies.

Comparison to Industry Standards

• The acquisition of NeuroMetrix by electroCore is similar to other acquisitions in the medical device and bioelectronic medicine sectors, where larger companies acquire smaller firms to expand their product portfolios and market reach.
• The use of contingent value rights (CVRs) is a common mechanism in mergers and acquisitions, particularly in the biotech and pharmaceutical industries, to address uncertainties related to future product performance or regulatory milestones.
• The estimated $9 million net cash payout to NeuroMetrix shareholders, while subject to adjustments, is a typical component of such transactions, providing immediate value to shareholders.
• The royalty structure for the CVRs, with a cap of $500,000, is a common approach to incentivize future performance of the acquired assets while limiting the acquirers financial exposure.

Stakeholder Impact

• NeuroMetrix shareholders will receive cash and contingent value rights.
• Patients with chronic pain are expected to have expanded access to Quell technology.
• Physicians and patients will continue to benefit from the DPNCheck platform through its divestiture.

Next Steps

• NeuroMetrix will file a proxy statement with the SEC.
• NeuroMetrix will mail the definitive proxy statement and a proxy card to each stockholder.
• NeuroMetrix shareholders will vote on the adoption of the merger agreement.
• The transaction is expected to close late in the first quarter of 2025.

Key Dates

Keywords

merger, acquisition, NeuroMetrix, electroCore, shareholders, contingent value rights, CVR, net cash, DPNCheck, Quell, neuromodulation, divestiture